Eisai Co. Ltd., of Tokyo, said it signed a deal with Merck & Co. Inc., of Kenilworth, N.J., to increase the target number of endometrial carcinoma patients to be enrolled in a phase Ib/ II study of its in-house discovered and developed multikinase inhibitor, lenvatinib mesylate (marketed as Lenvima/Kisplyx), in combination with Merck's anti-PD-1 therapy, Keytruda (pembrolizumab), due to encouraging initial data.